Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26238112 | 0.87 | NAMPT (0.41) | MAPTNAMPTCYP11B1CYP11B2ELANE | |
| SCHEMBL29367068 | 0.87 | NAMPT (0.41) | MAPTNAMPTCYP11B1CYP11B2ELANE | |
| SCHEMBL26238420 | 0.83 | NAMPT (0.46) | MAPTNAMPT | |
| SCHEMBL29364869 | 0.82 | HSD17B13 (0.49) | MAPTNAMPT | |
| SCHEMBL25228957 | 0.82 | HSD17B13 (0.49) | MAPTNAMPT | |
| SCHEMBL25230765 | 0.80 | CYP11B2 (0.47) | MAPTCYP11B1CYP11B2ELANEG6PD | |
| SCHEMBL30426682 | 0.80 | CYP11B2 (0.47) | MAPTCYP11B1CYP11B2ELANEG6PD | |
| SCHEMBL25206285 | 0.80 | CYP11B2 (0.47) | MAPTCYP11B1CYP11B2ELANEG6PD | |
| SCHEMBL29364970 | 0.80 | CYP11B2 (0.47) | MAPTCYP11B1CYP11B2ELANEG6PD | |
| SCHEMBL29052562 | 0.79 | CYP11B2 (0.45) | MAPTCYP11B1CYP11B2ELANEG6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286923-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4185380-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | Inipharm, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286923-A1 | QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B1, HSD17B13 | MAPT 3039/4885NAMPT 675/4885ADORA3 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.